Importantly, when the tumour-initiating cells were treated with gemcitabine and, at the same time, the CXCL10-CXCR3 axis was disrupted by the treatment with nanovesicles that contained CXCR3 antagonist, the treatment delayed tumour regrowth. Here, CXCL10 is linked to neoplasm.